Scrip
Novavax and Rovi end vaccine agreement
08 February 2010
Simon Varcoe
Please Login to read the full article.
08 February 2010
Simon Varcoe
simon.varcoe@informa.com
Novavax has ended negotiations with
Rovi Pharmaceuticals in pursuit of a collaboration to develop Novavax's virus-like-particle (VLP)-based vaccines against influenza in Spain. The split was blamed on the two companies' "inability to agree on acceptable terms of the proposed collaboration and to...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Interview: Lupin set for Latin American buy as it expands internationally
- Governments face decision on which seasonal flu jab to buy after WHO includes H1N1
- Germany and Spain change swine flu vaccine orders
- Sanofi-Aventis's Q1 boosted by emerging markets and H1N1 as hopes for Eloxatin growth return
FEATURES
- Face-to-Face: Trophos - The French firm that hooked Actelion
- GE Healthcare aims to end unpredictability in early drug research
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
